Xtalks Community Connection Newsletter - June 2026

Xtalks Community Connection Newsletter - June 2026

The June edition of our community newsletter is live, bringing you expert insights on real-world evidence, orphan drug pricing and the future of clinical trial monitoring. Be sure to explore our latest content to learn:

  • How real-world evidence is shaping inclusive and diverse clinical trials with Takeda CMO Dr. Awny Farajallah
  • The commercial and manufacturing drivers behind the most expensive drugs on the market in 2026
  • How the industry feels about regulators relying on AI to accelerate drug approvals in our latest poll results

Plus, don't miss our community updates: dive into the latest life science job openings, cast your vote on whether real-time clinical trials will become the new industry standard and catch up on the latest industry trends!

Article content

Check out our upcoming and on-demand webinars (see all) on essential life science industry topics, including:

Clinical Trials [See All]

Pharmaceutical Regulation [See All]

Drug Discovery & Development [See All]

Pharma Manufacturing & Supply Chain [See All]

Medical Devices [See All]

Article content

The Most Expensive Drugs on the Market in 2026 — and Why They Cost So Much

Article content

From Lenmeldy to Zolgensma, the most expensive drugs in 2026 show how rare disease science, specialized manufacturing and upfront payment models are testing healthcare systems... (read more)

Article content

How Real-World Evidence Is Shaping Inclusive Clinical Trials with Takeda CMO Dr. Awny Farajallah

Article content

In this week’s episode of the Xtalks Life Science Podcast, host Ayesha Rashid, Senior Life Science Journalist at Xtalks, spoke with Awny Farajallah, MD, Chief Medical Officer at Takeda, about the growing role of real-world evidence in improving clinical trial inclusivity and diversity... (read more)

Article content

This Month's Question

Article content

Regulators, sponsors and technology providers are exploring new ways to improve trial efficiency, data quality and decision-making. One emerging area is real-time clinical trial monitoring, where trial data may be reviewed and analyzed more continuously rather than only at traditional milestones. Will real-time clinical trials become the new standard for drug development? Cast your vote here and join the conversation!

Last Month's Results

Article content

The results of last month’s poll are now available — check out the extent to which your peers believe regulators should rely on AI to accelerate drug approvals.

Article content

Below are some exciting job opportunities from our member organizations. Click here to explore all the open positions on our website today.

Manufacturing [See All]

Drug Discovery [See All]

Article content


To view or add a comment, sign in

More articles by Xtalks

Explore content categories